New link between sulfur metabolites in gut microbiome and neurodegenerative diseases revealed

FHS
June 17, 2024
3:23 am

Neurodegenerative diseases (NDDs), which have no known cures and elusive causes, result in irreversible damage to the brain and nervous system.

Risk adjusted net present value: What is the current valuation of AstraZeneca’s AZD-9574?

AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer.

April 17, 2024

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics.

March 11, 2024

Eli Lilly’s Zepbound eases obstructive sleep apnea in trials

Eli Lilly reported positive results of its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity

April 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.